Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries (Q87904572)

From Wikidata
Jump to navigation Jump to search
scientific article published on 17 May 2014
edit
Language Label Description Also known as
English
Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries
scientific article published on 17 May 2014

    Statements

    title
    Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries (English)
    1 reference
    stated in
    Europe PubMed Central
    PubMed ID
    24840612
    reference URL
    https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24840612%20AND%20SRC:MED&resulttype=core&format=json
    retrieved
    18 March 2020

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit
                      Retrieved from "https://www.wikidata.org/w/index.php?title=Q87904572&oldid=1410766469"